FDA Advisory Panel Backs Replimune's RP1, Bringing The Melanoma Therapy One Step Closer To Approval
Replimune Group, Inc. (REPL) has secured a favourable FDA advisory committee vote for its lead therapy RP1 in advanced melanoma, with a final FDA decision expected by August 2, 2026. RP1 in combination with Bristol Myers Squibb's Opdivo (nivolumab) is proposed for the treatment of advanced melanoma.
How this was made
The 30-second read
Why it matters
The key new information is the panel’s 10 to 3 vote that RP1’s efficacy results are clinically meaningful, which typically strengthens the approval case ahead of the FDA’s Aug 2 decision.
Market read
Traders can position for a binary regulatory catalyst into Aug 2, using the advisory vote as a probability-weighting input.
What to watch
The panel’s discussion centered on whether IGNYTE was sufficient to assess response rate and duration; any FDA request for further data could cap upside despite the vote.
Background
CTGTAC reviewed Replimune’s BLA resubmission for RP1 in advanced melanoma, using data from the single-arm IGNYTE phase I/II study in combination with Opdivo.
Ticker impact
Replimune’s FDA advisory panel voted 10 to 3 that RP1’s IGNYTE efficacy is clinically meaningful, with an FDA decision due Aug 2, 2026.
Bullish bias into Aug 2, with elevated volatility around any FDA follow-up questions or label conditions.
The article reports a favorable CTGTAC vote on RP1 efficacy and ties it to a specific upcoming FDA decision date, which typically drives event-risk repricing.
Market effects
Supports sentiment for oncology cell or gene-therapy style platforms and for melanoma combination strategies involving PD-1 inhibitors.
Primarily US biotech event risk, with potential spillover to small-cap biotech sentiment.
Could influence global investor appetite for advanced melanoma programs and similar immunotherapy-adjacent modalities.
Counterpoint
A favorable advisory vote is not binding, and the FDA could still require additional evidence on durability or response rate given the single-arm design.
Key entities
- companyReplimune Group, Inc.
Sponsor of RP1, whose BLA resubmission for advanced melanoma was reviewed by the FDA advisory committee.
- therapyRP1
Replimune’s lead therapy evaluated in the IGNYTE study for advanced melanoma.
- therapyOpdivo (nivolumab)
Bristol Myers Squibb’s PD-1 inhibitor used in combination with RP1 in IGNYTE.
- regulator_advisory_bodyFDA Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC)
Advisory committee that voted 10 to 3 on whether RP1 efficacy results are clinically meaningful.
